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Abstract 
Compared with conventional cancer treatments, the main advantage of oncolytic virotherapy is its tumor-selective 
replication followed by the destruction of malignant cells without damaging healthy cells. Accordingly, this kind of 
biological therapy can potentially be used as a promising approach in the field of cancer management. Given the 
failure of traditional monitoring strategies (such as immunohistochemical analysis (in providing sufficient safety and 
efficacy necessary for virotherapy and continual pharmacologic monitoring to track pharmacokinetics in real-time, 
the development of alternative strategies for ongoing monitoring of oncolytic treatment in a live animal model seems 
inevitable. Three-dimensional molecular imaging methods have recently been considered as an attractive approach 
to overcome the limitations of oncolytic therapy. These noninvasive visualization systems provide real-time follow-up 
of viral progression within the cancer tissue by the ability of engineered oncolytic viruses (OVs) to encode reporter 
transgenes based on recombinant technology. Human sodium/iodide symporter (hNIS) is considered as one of the 
most prevalent nuclear imaging reporter transgenes that provides precise information regarding the kinetics of 
gene expression, viral biodistribution, toxicity, and therapeutic outcomes using the accumulation of radiotracers at 
the site of transgene expression. Here, we provide an overview of pre-clinical and clinical applications of hNIS-based 
molecular imaging to evaluate virotherapy efficacy. Moreover, we describe different types of reporter genes and their 
potency in the clinical trials.
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Background
While tumor imaging and radiotherapy strategies are cru-
cial for tumor identification and treatment, the presence 
of metastasis and radiation resistance has reduced the 
efficacy of treatment in cancer patients. Consequently, 
finding novel methods for increasing the efficiency of 
tumor imaging and treatment is of great importance [1, 
2]. Recently, oncolytic virotherapy has provided a new 
outlook for the therapy of malignancies with promis-
ing outcomes [3, 4]. Oncolytic viruses (OVs) specifically 
induce cancer cells death by infection of and spreading 
on tumor cells through different mechanisms such as 
direct lysis effect or adjacent cells fusion. The ability of 
OVs to selectively infect tumor cells is mainly associated 
with the disruption of type-I interferon pathway, which 
represents the first line of defense against viral infec-
tions. In this case, the stimulation of endoplasmic reticu-
lum (ER) stress and subsequent immunogenic cell death 
(ICD) process in OVs-infected cells elicit a range of anti-
tumor immune responses. This stress condition can also 
lead to the attraction of immune cells, notably antigen 
presenting cells (APCs) (i.e. immature dendritic cells), 
natural killer cells (NK cells), and cytotoxic T-cells to the 
site of infection [5, 6].
Upon the stage of tumorigenesis, down-regulation of 
the major histocompatibility complex class-I (MHC-I) 
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molecules and also the overexpression of the stress-
induced ligands on the surface of malignant cells to avoid 
recognition by cytotoxic T-lymphocytes (CTLs), make 
them more sensitive to NK cell-mediated death. In this 
manner, the reduced detection of self MHC-I molecules 
by NK cell-inhibitory receptors coupled with an increase 
in activating signals by recognition of stress-induced sur-
face ligands promote the cytolytic activity of NK cells. 
Of note, perforin and granzyme released by activated 
NK cells represent major lytic mediators involved in 
the destruction of tumor cells [7, 8]. On the other hand, 
the proliferation of oncolytic viruses into target cells 
and subsequent recognition of viral elements by pattern 
recognition receptors (PRRs) such as toll-like receptors 
can positively affect the development of the innate and 
adaptive immune responses against tumor cells (Fig.  1) 
[6].
To perceive and prognosticate therapeutic outcomes 
of therapy with OVs, various mathematical models have 
been expanded. The improvement of such models, which 
are capable of accurately measuring in  vivo dynamic 
proliferation, is accessible by means of technologies that 
allow quantitative real-time measurements in tumor 
cells. Accordingly, engineered OVs have attracted more 
attention in accurate tumor imaging and treatment 
because they are capable of expressing reporter genes 
Fig. 1 Schematic illustration of the multimodality role of virotheranostics in treatment and tracking of tumor cells. a Mechanisms by which 
oncolytic viruses (OVs) stimulate antitumor immunity. Virus-based immunostimulatory cytokine and chemokine expression can recruit and 
activate T cells, antigen-presenting cells (APCs), and natural killer (NK) cells, and subsequently, improve the therapeutic activity of OVs. Regardless 
of oncolysis, OVs stimulate innate immune receptors on professional antigen-presenting cells (APCs) such as dendritic cells and prime antitumor T 
cells. OVs are able to counteract immune suppression through several mechanisms, including stimulation of pro-inflammatory cytokines and TAAs 
production and also depletion of immunosuppressive cell types such as cancer-associated fibroblasts (CAFs) within the tumor microenvironment. 
OVs can also improve recognition of tumor cells by the immune system through upregulation of pathways involved in antigen processing 
and presentation, including increased major histocompatibility complex (MHC) class I and MHC class II expression on APCs and tumor cells. 
Subsequently, CD28 signaling will result in the activation of the CD8 + T cell. These activated CD8 + T cells will differentiate into effector T cells that 
can recognize the MHC class I-peptide complex on virally infected cells. Binding of the TCR to the MHC class I-peptide complex leads to activation 
of the CD8 + T cell and the release of cytokines. Moreover, NK cells play a pivotal role in detection and killing tumor cells, recruiting other immune 
cells, mediating T cell activation, and expanding and releasing chemokines and cytokines. The activation of NK cells depends upon the presence 
of local cytokines such as IL-12. Regulation of NK cells is achieved through binding of inhibitory cell surface receptors such as the killer-cell 
immunoglobulin receptors (KIRs) (not shown), which bind to different human leukocyte antigen (HLA) complexes on tumor cells. Upon some 
circumstances of cellular stress like viral infection, associated ligands for activating receptors are often upregulated and MHC class I expression may 
be downregulated. The upregulation of activating ligands and downregulation of MHC class I produce a signal for NK cells to become activated and 
play their effector functions. b Visualization of tumor cells through NIS-mediated cell imaging. Following transduction with the viral vector carrying 
the NIS gene, cancer cells are capable of transporting radioisotopes for imaging purposes. Tissue-specific promoter enables the NIS gene to express 
specifically in corresponding cancer cells, providing a promising strategy of cancer-targeting therapy and imaging. The cells can be imaged by 
radionuclide-based molecular imaging techniques using gamma-ray or positron-emitting radiotracers. Expression of sodium iodide symporter (NIS) 
reporter gene leads to the insertion of sodium iodide symporters into the cell membrane, where they import many reporter probes like  TcO4−, 
 ReO4−, and  At−, along with sodium ion (Na +), into the cytosol. Imaging is performed with SPECT or PET and the results are like example pictures at 
top of panel B, in which tumor area has been determined by red circle
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and demonstrating treatment efficacy in addition to kill-
ing cancer cells [9, 10]. Oncolytic measles virus (OMV) 
as a derivative of the Edmonston vaccine strain is an RNA 
virus belonging to the Paramyxoviridae family, which its 
employment safety has been confirmed in many human 
malignancies [11, 12]. The OMV demonstrates a tropism 
for the CD46 membrane protein, part of the complemen-
tary regulatory pathway, which is expressed at high levels 
on tumors compared to normal cells. Infection of tumor 
cells by OMV induces cell death via apoptosis and syncy-
tia formation [13].
Many preclinical studies have shown high efficacy of 
OMV vectors in melanoma, ovarian, and hepatocellu-
lar and squamous cell carcinoma models. Measles virus 
expressing the sodium iodide symporter (NIS) is an 
Edmonston vaccine strain of MV, engineered to express 
the NIS as the most prevalent imaging reporter gene. The 
NIS gene expression by OMV enables noninvasive moni-
toring of cancer cells and enhances anti-tumor response 
through the uptake of radiolabeled iodine [14]. In this 
review, the use of NIS-based molecular system to com-
bine virotherapy and molecular imaging areas in pre-
clinical and clinical settings, as well as the ability to use 
different types of reporter genes in the clinical trials will 
be studied.
Obstacle and approaches for improving virotherapy
Two basic steps to increase the efficacy of oncolytic viro-
therapy are reaching the appropriate amount of virus at 
the tumor site and the spreading ability of the virus within 
the tumor tissue. Depending on the administration route 
of oncolytic viruses to cancer therapy, many barriers such 
as trapping virus particles by liver, spleen, or neutraliz-
ing antibodies, and activation of the immune responses 
against viral replication can hamper virus delivery to tar-
get organ and greatly impress the effectiveness of treat-
ment [15, 16]. The adaptive immune system has the most 
significant negative effect on treatment efficacy, which 
can affect both delivery and spread of the OMV in tumor 
tissue. Moreover, the presence of pre-existing antibodies 
against the measles virus reduces the efficacy of therapy 
in the intravenous route, especially in repeated systemic 
administration. However, different solutions have been 
suggested to reduce these effects [17]. One of these strat-
egies is the administration of cyclophosphamide (CPA) 
as an anticancer and suppressor agent to prevent tissue 
rejection in transplanted patients. CPA works by killing 
disturbing lymphocytes such as T, B, and NK cells. One 
study showed that the administration of CPA 1  week 
before OMV therapy increased oncolytic efficacy through 
short-term immunosuppression in tumor tissue [18, 19].
Another strategy to avoid neutralizing antibodies is the 
use of carrier cells. Various cells such as mesenchymal 
stem cells (MSCs), dendritic cells, and activated T cells 
can be used for this purpose. Due to their exceptional 
features such as homing to tumor tissues as well as 
immunomodulatory and self-renewal capacity, MSCs 
have received special attention and can be used for meta-
static cancers [20, 21]. Other strategies, such as the cov-
ering of oncolytic virus particles with nanoparticles and 
the construction of chimeric particles are also effective in 
reducing the malfunction of the immune system. A study 
by Mader et al. revealed that despite the presence of neu-
tralizing antibodies, MSC-loaded OMV induced syncy-
tia formation in an orthotopic ovarian cancer model and 
increased survival compared to naked OMV or unin-
fected MSC groups [20].
Overall‑molecular imaging
Molecular imaging is a powerful tool that enables clinical 
studies to noninvasively and serially detect viral targeting 
sites. Additionally, the viral infection level is also meas-
urable through molecular imaging, which can provide 
information on the toxicity, efficacy, and safety profile of 
oncolytic viruses [22, 23]. Generally, real-time tracking of 
virus evolution can optimize treatment by providing use-
ful information regarding the viral dose and administra-
tion schedule, as well as the elimination of the need for 
multiple and repeated tissue biopsies. Moreover, the abil-
ity of molecular imaging to improve vector design and 
clinical protocols facilitates the use of personalized medi-
cine in the treatment of cancer [22, 24–26].
There are various imaging modalities for molecular 
imaging and based on the employed molecular probe 
are divided into two groups including non-nuclear and 
nuclear molecular imaging modalities. Bioluminescence 
and fluorescence imaging devices (e.g. charge-coupled 
device (CCD) cameras) are the most common imaging 
modalities applied in non-nuclear medicine. These exter-
nal imaging devices use light as a nonradioactive probe 
and are predominantly restricted to preclinical assays 
[25, 27]. Nevertheless, nuclear molecular imaging tools 
such as SPECT, positron emission tomography (PET) 
scanner, and gamma camera modalities can potentially 
be used in clinical trials and due to their ability to recog-
nize and localize the gamma-ray emitted by a radioactive 
tracer decay, they can provide more reliable informa-
tion about virotherapy outcomes. These scanners are 
also very sensitive and yield better spatial resolution [9, 
27]. To improve the spatial resolution and provide more 
information concerning the anatomy of target tissues and 
the level of gene expression, metabolism, and receptor 
distribution, hybrid imaging systems using the combina-
tion of visualization instruments such as PET and SPECT 
with computed tomography (CT) or magnetic resonance 
imaging (MRI) have been developed [28].
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Of note, serial monitoring of infection, prediction of 
the primary site of tumors and metastases, as well as 
evaluation of antitumor efficacy are possible using the 
genetically engineered viruses that express a reporter 
gene, which can be imaged by molecular imaging 
modalities [22, 25, 28]. In this manner, the accumu-
lation of tracer molecules at the site of transgene 
expression and recognition of their emitted signals 
by external imaging devices is used to follow the viral 
evolution in tissues of interest. It is worth noting that 
these targeting moieties or signaling agents introduced 
as imaging molecular probes should not be immuno-
genic, or otherwise interfere with the function of sub-
ject cells [25, 27, 29].
Regarding the use of radioactive and non-radioac-
tive substrates as targeting moieties, molecular imag-
ing methods are broadly categorized into optical and 
deep-tissue imaging systems [25]. In the following sec-
tions, we will focus on the most investigated reporter 
transgenes based on the type of imaging technique 
(Table 1). The mechanism of molecular imaging meth-
ods based on reporter genes is shown in Fig. 2.
Optical imaging
Optical detection techniques are introduced as a 
promising approach to evaluate oncolytic viruses’ 
activity in small living subjects using non-nuclear 
molecular imaging modalities and include fluores-
cence and bioluminescence imaging [25, 30]. Due to 
its radiation safety profile, quick performance, and low 
cost, optical imaging is considered as the main non-
invasive visualization method in preclinical assays. 
However, the application of these techniques for deep-
tissue imaging has been limited by light scattering in 
biological tissues, auto-fluorescence emitted by dead 
cells, and presence of cellular inhibitors of excitation 
below 600 nm [25].
Fluorescence‑based reporter transgenes
Fluorescent proteins are broadly used for in  vivo imag-
ing of viral gene expression in small tumor-bearing 
animals. Jellyfish Aequorea Victoria-derived green 
fluorescence protein (GFP) is the most prevalent opti-
cal reporter transgene cloned into the oncolytic viral 
genome. However, due to the limited penetration depth 
of light required for GFP excitation and emission, this 
reporter protein commonly used for following the coloni-
zation of OVs in tumors and metastases close to the body 
surface [25, 29]. In order to optimize the brightness and 
increase the structural stability of GFP without disturb-
ing its function as a reporter protein, mutation screen 
has run and among the recombinant constructs, a human 
codon-optimized variant of GFP, enhanced GFP (eGFP, 
F64L/S65T), has shown prominent results in molecu-
lar imaging assays [31]. Better packing of the eGFP due 
to geometrical properties of L64 in comparison with F64 
in GFP improves the stability of protein and adds extra 
capacity for inter-residual communication, resulting in 
improved function in different contexts [32].
Luciferase‑based reporter transgenes
Luciferase-mediated bioluminescence imaging (BLI) 
has been initially used to follow the evolution of 
spreading infection within target tissues in small living 
animals. In this system, the intensity of emitted light 
depends on the enzyme efficacy in catalyzing the biolu-
minescence reaction and the concentration of substrate 
and cofactor (ATP-Mg2+) [25, 33]. Compared with fluo-
rescence, the luminescence system is more sensitive 
due to the lower background noise levels. Therefore, 
this approach is more applicable than fluorescence for 
whole-body imaging and the prediction of the primary 
site of near-surface tumors and metastases. However, 
given the low spatial resolution, BLI is not available for 
large animals and is limited to experimental models [25, 
Fig. 2 Schematic illustration of tumor cell imaging using noninvasive visualization systems by means of measles viruses (MVs) to encode reporter 
transgenes based on recombinant technology. a Optical imaging. Transcription and translation of the firefly luciferase (FLUC) gene lead to the 
accumulation of the firefly luciferase enzyme, which subsequently catalyzes a photochemical reaction in the presence of D-luciferin. This reaction 
yields low levels of fluorescence photons that can be detected and quantified by a charge-coupled device camera (CCD). b Enzyme-mediated 
imaging. Inside the transfected cells, HSV-1-tk is transcribed and translated to produce the HSV-1-tk enzyme.  [124I]-FIAU is a labeled nucleoside 
analog substrate for HSV-1-tk. In the presence of HSV-1-tk, the radiolabeled probe is phosphorylated and trapped within the cell. Radioactive 
decay of 124I isotopes can be detected with PET. The magnitude of  [124I]-FIAU signal reflects the activity of HSV-1-tk enzyme and thus HSV-1-tk gene 
expression. c Transporter/Symporter-mediated imaging. Tumor cells would acquire the function of iodine uptake with NIS gene transduction by 
viral vector delivery. NIS transports 2 sodium ions and 1 iodide ion into the cytoplasm together. The electrochemical sodium gradient generated by 
the  Na+/K+ ATPase pump provides energy for this transfer. Gamma radiation of radiolabeled ligands such as  [131I]-MIBG provide enough radiation 
for PET imaging. d Receptor-mediated imaging. 3-(2′-[18F]fluoroethyl)spiperone (FESP) is a gamma-emitting radiolabeled reporter probe that 
interacts with the dopamine 2 receptor (D2R) to result in probe trapping on or in cells expressing the D2R gene. Viral delivery of the D2R gene into 
the infected tumor cells armors them with a monitoring system, which can be visualized by PET
(See figure on next page.)
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29]. Due to the small size, the luciferase substrate (lucif-
erin for firefly luciferase and coelenterazine for Renilla 
and Gaussia luciferases) easily crosses the plasma 
membrane and reaches to the target tissues; thereafter, 
the visible light emitted upon enzymatic oxidation of 
the substrate at the site of luciferase expression enables 
virus tracking [29, 33].
Deep‑tissue imaging
To address several limitations of optical imaging includ-
ing restricted application to small models, difficulties 
in quantitation, and limited depth penetration of a few 
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millimeters, the design of a more sophisticated molecu-
lar imaging technique is required [34]. Currently, based 
on enzymatic activity, specific receptors, and ion trans-
porter/symporter, three classes of reporter transgene 
for use in deep-tissue imaging are developed via nuclear 
medicine techniques [29]. We introduce these types of 
transgenes in the following sections.
Enzyme‑based reporter transgenes
Herpes simplex virus-1 (HSV-1) thymidine kinase (TK) 
gene is the most studied reporter transgene based on 
enzymatic activity. Oncolytic virus-mediated tumor 
eradication can be evaluated noninvasively using the 
phosphorylation of radiolabeled thymidine analogs 
such as  [125I or 124I]-FIAU (fial2′-fluoro-2′-deoxy-1-β-
d-arabinofuranosyl-5-iodouracil), as well as radiola-
beled guanosine analogs like 8-[18F]-fluoroganciclovir 
(18F-FGCV) and  [18F]-FHBG (9-(4-fluoro-3-hydroxy-
methylbutyl) guanine) by HSV-1-TK [25, 35]. After the 
phosphorylation of cell-permeable radiotracers, the neg-
ative charge of the phosphate group (polar form) traps 
them into the cytoplasm of cancer cells. Accordingly, the 
accumulation of trapped radiotracers can be used as an 
indicator for in vivo monitoring of viral oncolysis activ-
ity over time [36, 37]. The main advantage of the HSV-
1-TK/nucleoside analog system is its bystander-killing 
effect by transferring phosphorylated nucleoside analogs 
from infected cells to surrounding un-transduced tumor 
cells using the gap junctions or apoptotic vesicles, which 
enhances the efficacy of virotherapy [36, 38]. However, 
some disadvantages are attributed to this system includ-
ing (a) limited clinical usage due to the regulatory restric-
tions associated with the radiolabeled thymidine analogs 
as investigational drugs, and (b) increased undesirable 
immune responses related to the non-human origin of 
exogenous reporter gene [25].
Receptor‑based reporter transgenes
Specific receptors such as human somatostatin receptor 
2 (hSSRT2) and dopamine type-2 receptor (D2R) can be 
employed in serial monitoring of oncolytic viruses deliv-
ery into malignant cells through binding and trapping 
the radiolabeled ligands [29]. The hSSRT2 is typically 
found in human kidney cells, as well as in neuroendo-
crine tumors and is targeted by the high-affinity synthetic 
peptide pentetreotide. Regarding the ability of systematic 
administration of hSSRT2-expressing oncolytic viruses, 
intratumoral delivery of hSSRT2 allows tracking of all 
primary and metastatic tumor sites [39]. However, an 
important disadvantage of this reporter system is the 
need for prior radiolabeling of tracer molecules. Alterna-
tively, given the binding ratio of 1:1 between the receptor 
and its corresponding radiotracers, the sufficient signal 
for viral monitoring may not be produced during in vivo 
imaging [25]. The D2R is another human receptor that is 
exclusively expressed in the striatum and pituitary and is 
targeted by high-affinity radiolabeled ligands like 3-(2′-
[18F]fluoroethyl)spiperone (FESP). Therefore, in this visu-
alization system, the use of exogenous receptors do not 
elicit undesirable immune responses [40]. However, given 
the high lipophilicity of D2R ligands, the accumulation 
and excretion of validated D2R ligands in liver cells upon 
systemic administration are inevitable [41].
Transporter‑based reporter transgenes
Human norepinephrine transporter (hNET) is a  Na+/
Cl−-dependent cell-membrane transporter protein 
involved in the movement of norepinephrine, dopa-
mine, and epinephrine through the plasma membrane 
[25]. Although the expression of hNET is predomi-
nantly restricted to the central and peripheral sympa-
thetic nervous systems, it is also found at high levels in 
neuroendocrine tumors and is targeted by the clinically 
approved metaiodobenzylguanidine (MIBG) [25, 42]. 
Regarding some advantages attributed to hNET such as 
(a) the human origin of hNET and its local expression in 
normal tissues, and (b) the ability to radiolabel the MIBG 
with gamma-emitting radioisotopes of iodine (123I, 124I, 
and 131I), which results in serial imaging through SPECT 
and γ-camera imaging (123I, and 131I), as well as PET sys-
tem (124I), hNET can be employed as a potential human 
reporter gene for noninvasive imaging [25, 42].
Symporter‑base reporter transgene
Human sodium/iodide symporter (hNIS), a prevalent 
nuclear medicine reporter gene, is an integral glycopro-
tein of the basolateral cell membrane, enabling the thy-
roid gland follicular cells to regulate intracellular iodide 
trapping [39, 43]. This process is started by the NIS-
mediated co-transport of two sodium ions along with one 
iodide ion into thyrocytes. The required energy for this 
co-transport against the cellular electrochemical gradient 
is provided by the sodium/potassium  (Na+/K+) ATPase 
[43]. Following iodide  (I−) uptake, molecular iodine  (I2) 
is produced by the oxidation of iodide using thyroid per-
oxidase enzyme (TPO). Iodine is one of the important 
constituents of thyroid hormones (THs), which plays a 
pivotal role in THs synthesis [27, 44]. In this way, upon 
the process called iodide organification, oxidized iodide 
is covalently coupled to thyroglobulin (Tg), a protein 
found in the follicular lumen at high levels that serves as 
the precursor of thyroid hormones in iodinated form and 
also constitutes the storage form of iodine in the thyroid 
gland [27].
Besides iodide uptake, intracellular accumula-
tion of anionic substrates such as pertechnetate 
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 (TcO4−), perrhenate  (ReO4−), and astatide  (At−) can also 
be promoted by hNIS-expressing cells. Human sodium/
iodide symporter is distributed exclusively in thyroid tis-
sues and to a lesser extent in some extra-thyroidal tissues 
including salivary glands, gastric mucosa, and lactat-
ing mammary glands [44]. Since iodide organification is 
a unique feature of the thyroid cells, the ability to retain 
iodide in extra-thyroidal tissues is reduced. The exact 
physiological role of NIS transporter in extra-thyroidal 
tissues has not been clarified until now [27]. Experi-
mental observation also has shown that the delivery of 
the hNIS gene to non-thyroid tumor cells would trigger 
iodide uptake [44]. These findings suggest that ectopic 
hNIS expression in tissues of interest could play a signifi-
cant role in the real-time noninvasive molecular imaging 
using the intracellular accumulation of anionic radiotrac-
ers such as gamma-emitting radioisotopes of iodide (123I, 
124I, 125I, and 131I), 99mTcO4−, 188Re, and 211At at the site of 
gene expression [25].
Compared to other reporter genes, the use of NIS has 
several potential advantages including (a) the human-
origin of NIS and its clinically approved radiotracers; (b) 
no need for prior radiolabeling of iodide due to its radi-
otracer property, which reduces corresponding costs; (c) 
the ability to use various imaging systems such as PET, 
SPECT, and γ-camera imaging to monitor viral distribu-
tion due to the cellular uptake of various radioisotopes by 
NIS [25, 27]; (d) the provision of anatomical information 
of NIS-expressing infected cells by the combination of 
SPECT or PET with CT [22]; (e) the ability to reflect the 
cell viability due to lost NIS concentrative function upon 
cell apoptosis [22, 45]; (f ) improvement in sensitivity of 
detection due to the signal amplification through the 
transport-mediated concentrative intracellular accumu-
lation of substrate [46]; and (g) the ability to concentrate 
carrier-free radiotracers for convenient use [22].
Moreover, given the extensive emission range of β par-
ticles produced by 131I (0.4 mm), the likelihood of killing 
non-transduced malignant cells increases by irradiat-
ing with radiation emitted from adjacent infected cells. 
This effect, termed the “physical crossfire”, can poten-
tially be used in radiovirotherapy. However, it may also 
result in unwanted toxicity through damage to neighbor-
ing healthy cells [27, 47]. It is worth noting that combi-
nation of NIS-mediated imaging with ionizing radiation 
(e.g. 131I) may have a synergistic effect in cancer therapy, 
which can be attributed to viral replication increase in 
response to upregulation of some DNA repairing path-
ways or also α decay particles produced by 131I (0.2–
2.4 mm in path length) [48, 49].
One of the disadvantages of this reporter system is its 
inability to organify iodide in extra-thyroidal tissues, 
which reduces the intracellular retention capacity of 
radiotracers in NIS-transduced cells. In this regard, after 
intracellular uptake, efflux pump is employed to export 
the radiotracers out of the cell, which may interfere with 
in  vivo imaging. Nevertheless, it has been determined 
that radiotracers’ efflux occurs at slow rate. Thus, it seems 
that the residual of radiolabeled iodide is enough to gen-
erate the required signal for invasive in vivo imaging. Use 
of alternative strategies such as employing radiotracers 
with greater energy (e.g. 188Re) to enhance local signal or 
co-delivery of NIS and TPO to help iodide organification 
in non-thyroidal tumor cells can be useful to overcome 
this limitation [27, 44].
Another limitation of serial hNIS imaging is the prob-
ability of radiotracers uptake by both malignant and 
normal tissues due to the extensive distribution of hNIS 
protein in normal tissues, which can lead to reduced 
radiotracers accumulation into targets of interest [50]. 
Furthermore, iodide shows a complex and unfavorable 
biodistribution and a large percentage of radioiodide is 
accumulated in the thyroid (up to 25% of the injected 
dose in euthyroid patients). Pretreatment with thyroid 
hormones for several days will be required to reduce 
this uptake. Additionally, the administration of con-
trast media for radiological studies would significantly 
reduce radioiodide uptake by NIS-transduced cells due 
to the competition between radioiodide and stable iodide 
released from the contrast media (Table 1) [51, 52].
Tumor imaging using oncolytic measles virus
According to several investigations, oncolytic virus ther-
apy is a novel frontier for clinical trials [53]. The major 
purpose of replication-competent cancer virotherapy 
is to produce a safe and efficient therapeutic index with 
minimal toxicity [25, 54]. To date, many studies have 
revealed that attenuated measles virus of the Edmonston 
lineage (MV-Edm) has antitumor activity in several types 
of cancer and also is able to minimize the damages in 
normal cells as stated earlier [22, 55–60]. Recently, owing 
to the strong oncolytic potential of MV-Edm and the 
above-mentioned advantages of NIS as a reporter gene, 
several groups have developed an engineered, attenuated 
measles virus expressing the NIS gene (MV-NIS) to eval-
uate the feasibility of NIS reporter gene for noninvasive 
imaging and monitoring of MV-NIS delivery. Table 2 lists 
preclinical and clinical studies in which MV infection has 
been detected noninvasively using molecular imaging 
techniques, and also shows the mechanism of imaging of 
oncolytic MV by image-guided injection techniques.
Employing a recombinant MV-Edm expressing the 
hNIS, Dingli et  al. showed that intratumoral spread of 
MV-NIS can be monitored noninvasively in  vivo using 
serial gamma-camera imaging of 123I. In this study, 
NIS expression and 123I uptake were observed 9  days 
Page 8 of 17Keshavarz et al. Cancer Cell Int          (2020) 20:131 
following intravenous injection of MV-NIS into mice. 
The results of serial imaging after a single injection of 
MV-NIS demonstrated changes in iodide uptake owing 
to viral and tumor replication [56]. In another study, 
Carlson et al. have evaluated the use of NIS for monitor-
ing and quantitation of MV-NIS delivery, viral spread, 
and gene expression in pancreatic cancer [61]. Due to 
the close anatomical proximity of pancreas and stom-
ach, uptake of radioiodine in the stomach can produce 
strong signals that may overlap with pancreas signals and 
result in reducing spatial resolution. To resolve this prob-
lem and improve three-dimensional spatial resolution, 
the involvement of cross-sectional fusion imaging tech-
niques such as SPECT/CT and PET/CT is necessary. In 
this regard, planar and micro SPECT/CT images indicate 
tumor xenografts infected with MV-NIS concentrated 
radioiodine in vivo, providing serial noninvasive imaging 
and quantitation of radionuclide uptake [61].
In addition to the detection of heterogeneity in repli-
cation kinetics and biodistribution of infection, exploring 
the origin of heterogeneity is possible through the NIS-
mediated noninvasive imaging and monitoring [22]. A 
recent study by Penheiter et al. has successfully employed 
pinhole micro SPECT/CT imaging to resolve intratu-
moral viral dispersion patterns in a human pancreatic 
xenograft model infected with MV-NIS [62]. The results 
suggest that the use of micro SPECT/CT for localization 
and quantification of the oncolytic MV-NIS infection 
is less time-consuming and more cost-effective in com-
parison with autoradiography and immunohistochemical 
analysis that require animal killing [62]. In another study 
by the same group, the role of micro SPECT/CT in opti-
mizing the timing of MV-NIS-induced oncolysis and 
NIS-mediated 131I radiotherapy of human pancreatic 
cancer xenografts in athymic nude mice was determined. 
Serial imaging with 123I micro-SPECT/CT after virus 
injection revealed significant temporal variability in peak 
tumor iodide localization and tumor reaction after intra-
tumoral MV-NIS injection [59].
Deyle et al. were the first to show the feasibility of non-
invasive theragnostic potential of MV-NIS for malignant 
peripheral nerve sheath tumor (MPNST). In vivo moni-
toring of MV-NIS using 125I SPECT/CT imaging showed 
that radioiodine uptake in tumors infected with MV-NIS 
was approximately 2.5 times higher than control tumors. 
Consequently, MV-NIS propagation in MPNST tumors 
can be monitored noninvasively in vivo using 125I SPECT/
CT [55]. Galanis et  al. used NIS-mediated imaging to 
clinically monitor MV-NIS delivery in resistant ovarian 
cancer patients after intraperitoneal MV-NIS adminis-
tration every 4 weeks for up to 6 cycles. NIS expression 
was imaged by 123I uptake on SPECT/CT and in 3 out 
of 13 patients treated at the  109  TCID50 dose level, NIS 
expression was observed. The results showed that there 
is a temporal heterogeneity in the detection of NIS-medi-
ated radiotracer uptake, confirming differences in intra-
tumoral virus replication kinetics or initial intratumoral 
deposition of virus particles [58]. The results of a phase 
I trial showed that MV encoding NIS can be a treatment 
option for refractory multiple myeloma [57]. Russell et al. 
Table 1 Oncolytic viruses encoding reporter transgenes for various imaging modalities
CCD camera Charge-Coupled Device, EMCCD Camera Electron multiplying CCD camera, SPECT single-photon emission computed tomography, PET positron emission 
tomography
Visualization methods Reporter transgenes Oncolytic viruses encoding 
reporter transgenes
Imaging modalities Ref.
Optical imaging Fluorescent proteins (e.g., GFP, eGFP) Newcastle disease virus, 
measles virus, herpes simplex 
virus-1 (HSV-1), adenovirus, 
vaccinia virus (GLV-1h68), and 
Vesicular stomatitis virus (VSV)
Specially adapted CCD cameras 
to detect fluorescence
[25, 29, 33]
Luciferase Parvoviruses, adenoviruses, 
HSV-1, vaccinia virus, measles 
virus, and VSV
EM-CCD camera
Deep-tissue imaging Enzyme-mediated imaging (e.g., HSV-
1-TK)
Sindbis virus SPECT and PET scanner, and 
γ-scintigraphy
[27, 29, 36]
Receptor-mediated imaging hSSRT2 Vaccinia virus PET scanner and γ- scintigraphy [25, 27, 34, 40]
D2R Adenovirus PET scanner
Transporter/Symporter-medi-
ated imaging
h-NET Vaccinia virus (GLV-1h99) SPECT and PET scanner, and 
γ-scintigraphy
[42]
h-NIS Adenoviruses, measles, 
vesicular stomatitis, vaccinia 
virus (GLV-1h153), HSV, and 
Retrovirus
SPECT and PET scanner, and 
γ-scintigraphy
[25, 27, 44]
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presented imaging data and clinical response of two mea-
sles-seronegative myeloma patients treated with intrave-
nous infusion of  1011  TCID50 MV expressing NIS. Their 
results showed that uptake intensity is different among 
tumors of similar size, which proves the heterogeneity in 
viral replication even within the same patient. Further-
more, in both cases, the treatment resulted in M protein 
reduction and bone marrow plasmacytosis resolution 
[60].
Of note, the most important limitation of some imag-
ing techniques such as micro SPECT/CT and biolumi-
nescence is restricted spatial resolution (0.25  mm and 
1–2  mm, respectively) [63]. Alternatively, they provide 
information on the macroscopic scale. In an attempt to 
image the replication of an MV in vivo in tumors over a 
time span of several days at single-cell resolution, Kem-
ler et  al. have recently established an intravital imaging 
system using the dorsal skinfold chamber (DSFC) and 
two-photon microscopy. In this study, they compared the 
replication and oncolysis of a fusogenic and a hypofuso-
genic MV. The results showed distinctly different replica-
tion kinetics and phenotypes of these viruses at cellular 
level [63]. Preclinical and clinical studies have demon-
strated the ability of NIS-mediated imaging of radiotracer 
uptake to noninvasively monitor OMV replication and 
propagation. The results of ongoing clinical trials with 
MV expressing NIS show that NIS-mediated imaging 
can provide information about pharmacokinetics and 
treatment response for clinicians, but is  in  need  of  fur-
ther investigation for future clinical applications.
NIS‑mediated therapy
During the last two decades, different malignancies with 
various origins are under treatment by MV-NIS and the 
acquired results are highly promising. An early study 
on radiovirotherapy of myeloma tumors in mice rep-
resented complete regression of MV-sensitive tumors 
after MV-NIS administration and also regression of MV-
resistant tumors after the addition of 131I [56]. Msaouel 
et al. showed that the administration of a single dose of 
MV-NIS to prostate cancer xenografts in mice could sig-
nificantly increase tumor regression and prolong mice 
survival. Furthermore, subsequent administration of 131I 
significantly enhanced the effectiveness of the method 
and induced tumor eradication in 40–60% of cases. Inter-
estingly, increasing doses up to sixfold resulted in the 
complete elimination of tumors in 80% of mice models 
[64]. Similarly, in another survey, it has been demon-
strated that there is a correlation between the injection 
number and a reduction in tumor growth [61].
Other studies also have shown the lethal impact of MV-
NIS on various cancer types. While utilization of both 
MV-NIS alone or in combination with 131I resulted in the 
destruction of medulloblastoma cells in vitro and regres-
sion of mouse medulloblastoma xenografts, adminis-
tration of 131I yielded a stronger response [65]. Similar 
results were observed for SCCHN [66] and glioblastoma 
[67] in vitro and in vivo and an effective concentration of 
radioiodine 131I in the tumors following administration of 
MV-NIS was evident in both cases. The administration 
of this oncolytic agent mediates antitumor effect through 
inducing severe cytopathic effects (CPEs). Msaouel et al. 
Observed significant CPEs following the addition of MV-
NIS to prostate cancer cell lines [64]. The same CPEs 
were reported by Carlson et al. where syncytia formation 
and malignant cell death occurred after in vitro infection 
of human pancreatic cancer cell lines with MV-NIS [61]. 
Additionally, another study showed that MV-NIS admin-
istration induces considerable CPEs in MPNST cell lines 
[55]. In addition to their highly effective therapeutic 
role, these particles have acceptable safety and tolerabil-
ity [64]. In a clinical survey on ovarian cancer patients, 
dose-limiting toxicity did not occur even at high doses of 
MV-NIS [69] and also Russell et al. have reported that the 
mild toxicity of the MV-NIS-based therapy approach was 
eliminated within a week [60].
Many cancer types like prostate tumors have a strong 
expression level of measles receptor CD46 [68–71], 
which facilitates effective infection of tumor cells by this 
oncolytic virus. A study showed that higher expression 
of CD46 on myeloma tumors compared to healthy tis-
sues mediates tropism of the virus for malignant plasma 
cells and higher sensitivity of cancer cells to infection and 
destruction by MV-NIS [56]. Similarly, administration 
of MV-NIS into MPNST cell lines with the high expres-
sion level of the CD46 receptor on their surface resulted 
in severe CPEs, whereas normal cells suffered much less 
damage [55]. Due to this higher permissiveness of malig-
nant cells for MV-NIS, not only MV-NIS-based therapies 
in combination with systemic 131I result in a better thera-
peutic response in primary tumors than healthy tissue, 
but also mediate higher isotope uptake and therapeutic 
response in metastases compared to primary tumors 
[72]. Furthermore, in some specific cancers such as ana-
plastic thyroid cancer that are resistant to radioactive 
iodine therapy due to loss of NIS expression, the use of 
MV-NIS in combination with radioactive iodine can be 
employed as an effective alternative approach, allowing 
the elimination of this resistance and destruction of can-
cer cells both in vitro and in vivo [73].
Due to the lack of efficient antibody response in mye-
loma patients, the probability of neutralization of MV-
NIS particles by circulating antibodies is extremely lower 
among these patients than among the patients with other 
malignancies [56]. This result suggests that surviving the 
host immune response can play a decisive role in the 
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outcome of treatment with MV-NIS. Accordingly, it has 
been shown that the route of MV-NIS administration is 
effective in escaping the immune system and treatment 
outcome. Therefore, compared to intravenous injection, 
intratumoral administration of MV-NIS has a more sig-
nificant antitumor effect because of avoidance from the 
systemic immune response to measles [64]. Intratumoral 
MV-NIS therapy of human pancreatic cancer xenografts 
in mice resulted in a significant reduction in tumor vol-
ume and increased the survival time of the treated mice 
compared with the control mice [61]. However, the 
results of a study showed that there was no effective syn-
ergy between MV-NIS and 131I radiotherapy after the 
intratumoral injection of MV-NIS, which was clearly due 
to the lack of uniform distribution of MV-NIS infection 
within the BxPC-3 pancreatic tumors. It is while in stably 
NIS-expressing BxPC-3 tumors, rapid tumor regression 
occurred following administration of 131I [59].
To improve the function of MV-NIS particles, alter-
native methods are also under investigation. MV-NIS 
particles have a great potential for fusion-dependent cell-
to-cell propagation, which in addition to the destruction 
of noninfected tumor cells also can considerably pro-
tect the virus from neutralizing antibodies [17]. Lethally 
irradiated MM1 cells have been shown to still be able 
to express MV genes and can transmit this infection to 
other myeloma cells in the presence of measles immune 
serum that can be attributed to the cell-to-cell spread 
of MV-NIS infection. Additionally, in mice bearing dis-
seminated human myeloma, immunized with measles 
immune serum, administration of MV-NIS alone is not 
capable of inducing antitumor effect. However, lethally 
irradiated MV-NIS-infected MM1 cells can survive the 
passive antimeasles immunization and transmit MV-NIS 
infection to the cancer cells, leading to the destruction of 
tumor and increase in the survival of mice [74].
Co-administration of MV-NIS with other anticancer 
agents can be very helpful in progressing treatment and 
completing the treatment process. A study investigated 
the efficacy of MV-NIS for the treatment of ovarian can-
cer in athymic mice and showed that dual therapy with 
MV-CEA and MV-NIS has a better therapeutic effect 
compared to treatment with each virus alone [75]. In 
another survey, a combination of several therapeutic 
agents including MV-NIS, virally-directed 131I, External 
beam radiotherapy, and SAR-020106 (as Chk1 inhibi-
tor) was used as a quadruplet regimen. According to the 
obtained data, these agents had a synergistic effect on 
each other, which can ultimately improve the therapeu-
tic outcome of head and neck and colorectal cancers both 
in vitro and in vivo [76].
Along with continuous progress in MV-NIS-based 
preclinical studies, the next step is to conduct detailed 
and extensive clinical studies on patients with different 
cancers to tailor this method to therapeutic purposes. 
Patients with relapsing drug-refractory myeloma who 
received systemic administration of MV-NIS with radi-
oiodine showed a good response to treatment [60]. In 
another clinical trial of MV-NIS for drug-resistant ovar-
ian cancer therapy, the results indicated a significant 
increase in median overall survival among the patients. 
The results also showed that treatment with MV-NIS 
strongly stimulates the effector T cells against tumor anti-
gens, leading to an effective antitumor cellular immune 
response [58]. A Phase I clinical trial employed MV-NIS 
alone or in combination with cyclophosphamide for tar-
geted infection and extensive destruction of myeloma 
cells, and the results were highly satisfactory [57]. Incor-
porating findings from pre-clinical surveys into the clini-
cal phase will gradually provide the basis for integrating 
therapeutic approaches to develop more advanced MV-
NIS-based therapies.
NIS tracking of tumor therapy
MV-NIS particles are not only used in the treatment 
of various cancers, but also in tracking the outcome of 
treatment and helping to achieve more accurate imag-
ing of tumors and tracing cancer cells with contrast agent 
concentration inside the tumor. 123I or 99TcO4− micro-
single-photon emission CT/CT has been used for imag-
ing the mice with BxPC-3 xenografts and showed a great 
tumor infection rate and radionuclide uptake. The results 
substantiated that accurate localization of MV-NIS infec-
tion through a noninvasive tumor tracking system can 
replace costly and time-consuming methods like autora-
diography and immunohistochemistry [62]. In another 
study, human BxPC-3 pancreatic tumor xenografts in 
mice were imaged with micro-CT and micro-SPECT/CT 
after direct injection of contrast agent/MV-NIS mixture 
into tumors in order to track viral distribution within the 
tumor. This method allows accurate determination of the 
intratumoral viral distribution and real-time viral propa-
gation and is appropriate for MV-NIS monitoring pur-
poses [77]. Jung et al. reported that NIS expression using 
oncolytic MV can concentrate radioisotopes in infected 
cells in vitro and in vivo and the accumulation of radio-
isotopes can be quantitatively imaged by SPECT/CT. 
Their imaging results, both in vitro and in vivo, revealed a 
direct relationship between infectious virus particles and 
radioisotope uptake [78]. An intravital imaging system 
was successfully used by Kemler et  al. in non-invasive 
imaging of tumor cells after injection of a fluorophore-
expressing MV into the tumor. The fusogenic virus had 
a remarkably fast replication and developed numerous 
infection centers along with the formation of several 
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syncytia [63]. Such methods enable the determination 
of in  vivo distribution pattern and concentration sites 
of MV-NIS particles within the tumor tissue, helping 
to determine the dissemination of tumors and also the 
effectiveness of the treatment process.
Conclusion
The ability to selectively transduce recombinant oncolytic 
viruses to the tissues of interest together with the emer-
gence of molecular imaging techniques provide real-time 
quantitative information about both the pharmacokinet-
ics and pharmacodynamics of viral therapy, allowing per-
sonalized treatment of cancers. With current advances in 
molecular imaging, it has been possible to visualize intra-
tumoral infections in more detail and with higher reso-
lution. Recently, NIS-mediated nuclear imaging has been 
rapidly developing for pre-clinical and clinical applica-
tions to optimize treatment parameters such as the viral 
dose, route of administration, and vector design. In this 
system, changing the biodistribution of a radioisotope 
at the site of reporter gene expression provides accurate 
insight into the viral evolution and locations of transgene 
expression over time. Collectively, genetically modified 
viruses along with molecular imaging techniques play 
crucial role in improving therapeutic outcomes and thus 
appear to be promising approaches for cancer therapy.
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